VEKIRAX is developed by HaEmek Medical Center, Israel.

What development phase is VEKIRAX in?

VEKIRAX is FDA-approved (marketed).

Last reviewed 2026-05-13 · How we verify

VEKIRAX

HaEmek Medical Center, Israel · FDA-approved active Small molecule Quality 4/100

At a glance

Generic name	VEKIRAX
Also known as	Ombitasvir+Paritaprevir+Ritonavir
Sponsor	HaEmek Medical Center, Israel
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VEKIRAX CI brief — competitive landscape report
VEKIRAX updates RSS · CI watch RSS
HaEmek Medical Center, Israel portfolio CI